RARE — Ultragenyx Pharmaceutical Inc. stock price, charts and financials
QT50Ultragenyx Pharmaceutical Inc.Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -6.11 | Insider Own | 4.11% | Shs Outstand | 98.49M | Perf Week | -7.40% |
| Market Cap | 2.45B | Forward P/E | - | EPS next Y | -0.64 | Insider Trans | -3.53% | Shs Float | 94.61M | Perf Month | -23.07% |
| Enterprise Value | 3.48B | PEG | 0.84 | EPS next Q | - | Inst Own | - | Short Float | 14.20% | Perf Quarter | 0.89% |
| Income | -596.66M | P/S | 3.66 | EPS this Y | 29.42% | Inst Trans | - | Short Ratio | 6.24 | Perf Half Y | 2.64% |
| Sales | 669.43M | P/B | - | EPS next Y | 85.10% | ROA | -47.02% | Short Interest | 13.44M | Perf YTD | 8.30% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | 1566.94% | 52W High | 40.06 -37.55% | Perf Year | -8.22% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -53.86% | 52W Low | 18.37 36.19% | Perf 3Y | -40.89% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 22.85% 19.95% | Gross Margin | 83.57% | Volatility | 5.88% 4.95% | Perf 5Y | -69.89% |
| Dividend TTM | - | EV/Sales | 5.20 | EPS Y/Y TTM | 2.86% | Oper. Margin | -83.92% | ATR (14) | 1.50 | Perf 10Y | -52.39% |
| Dividend Ex-Date | - | Quick Ratio | 1.85 | Sales Y/Y TTM | 19.46% | Profit Margin | -91.03% | RSI (14) | 33.85 | Recom | 2.24 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.02 | EPS Q/Q | -17.20% | SMA20 | -16.50% | Beta | 0.32 | Target Price | 46.80 |
| Payout | 0.00% | Debt/Eq | - | Sales Q/Q | -2.16% | SMA50 | -9.10% | Rel Volume | 0.70 | Prev Close | 24.91 |
| Employees | 1,371 | LT Debt/Eq | -16.37 | Earnings | Aug 04 | SMA200 | -7.79% | Avg Volume | 2.18M | Price | 25.02 |
| IPO Date | Jan 31, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -23.67% -14.03% | Net Debt/EBITDA | -2.04 | Volume | 1,537,372 | Change | 0.44% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-13-26 | Reiterated | Wedbush | Neutral | $26 → $30 |
| Jul-07-26 | Reiterated | RBC Capital | Outperform | $35 → $40 |
| May-08-26 | Reiterated | Wedbush | Neutral | $27 → $26 |
| May-08-26 | Reiterated | Guggenheim | Buy | $52 → $43 |
| Apr-29-26 | Reiterated | Barclays | Overweight | $44 → $43 |
| Apr-16-26 | Reiterated | Morgan Stanley | Overweight | $50 → $67 |
| Mar-24-26 | Downgrade | Goldman Sachs | Buy → Neutral | |
| Mar-12-26 | Reiterated | Leerink Partners | $85 → $60 | |
| Feb-18-26 | Reiterated | Evercore ISI | Outperform | $37 → $34 |
| Feb-17-26 | Reiterated | Evercore ISI | Outperform | $39 → $37 |
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 669 | 673 | 560 | 434 | 363 | 351 | 271 | 104 | 51 | |
| Cost of Goods Sold Incl. D&A | 110 | 109 | 77 | 45 | 28 | 16 | 6 | 9 | 1 | |
| Gross Profit | 559 | 564 | 484 | 389 | 335 | 335 | 265 | 95 | 50 | |
| Selling, General and Administrative Excl. Other | 351 | 349 | 322 | 310 | 278 | 220 | 183 | 162 | 128 | |
| Research and Development | 771 | 750 | 698 | 648 | 706 | 497 | 412 | 357 | 294 | |
| Other Operating Expense | -1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | -562 | -535 | -536 | -569 | -649 | -382 | -330 | -424 | -371 | |
| Interest Expense | 68 | 62 | 63 | 66 | 43 | 29 | 33 | 1 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 24 | 26 | 31 | 27 | -10 | -42 | 178 | 26 | 174 | |
| Net Income Before Taxes | -606 | -571 | -568 | -608 | -702 | -453 | -185 | -399 | -197 | |
| Income Taxes | 4 | 4 | 2 | -2 | 6 | 1 | 1 | 3 | 1 | |
| Consolidated Net Income | -609 | -575 | -569 | -607 | -707 | -454 | -187 | -403 | -198 | |
| Net Income From Continuing Operations | -609 | -575 | -569 | -607 | -707 | -454 | -187 | -403 | -198 | |
| Net Income | -609 | -575 | -569 | -607 | -707 | -454 | -187 | -403 | -198 | |
| EPS (Recurring) | -6.11 | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | |
| EPS (Basic, Before Extraordinaries) | -6.11 | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | |
| EPS (Diluted) | -6.11 | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | |
| EBITDA | -503 | -474 | -469 | -516 | -640 | -410 | -140 | -390 | -178 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.78 | 3.38 | 6.84 | 8.15 | 8.93 | 16.29 | 31.16 | 23.41 | 42.63 | |
| Gross Margin | 83.56 | 83.80 | 86.43 | 89.63 | 92.29 | 95.44 | 97.79 | 91.35 | 98.04 | |
| Operating Margin | -84.01 | -79.49 | -95.71 | -131.11 | -178.79 | -108.83 | -121.77 | -407.69 | -727.45 | |
| Net Margin | -91.03 | -85.44 | -101.61 | -139.86 | -194.77 | -129.34 | -69.00 | -387.50 | -388.24 | |
| Shares Outstanding | 101 | 99 | 91 | 74 | 70 | 68 | 61 | 57 | 50 | |
| Market Capitalization | 2,527 | 2,277 | 3,828 | 3,539 | 3,243 | 5,718 | 8,444 | 2,434 | 2,174 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Horn Howard | Chief Financial Officer | Jul 01 '26 | Sale | 33.13 | 4,698 | 155,645 | 100,991 | Jul 06 |
| Sanders Corazon (Corsee) D. | Director | Jun 15 '26 | Sale | 25.05 | 2,000 | 50,100 | 21,095 | Jun 15 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | Jun 15 '26 | Sale | 24.62 | 1,899 | 46,753 | 94,462 | Jun 15 |
| Horn Howard | Chief Financial Officer | Jun 01 '26 | Sale | 23.77 | 4,653 | 110,602 | 105,689 | Jun 01 |
| SULIMAN SHEHNAAZ | Director | May 18 '26 | Sale | 25.12 | 5,740 | 144,189 | 27,951 | May 18 |
| Crombez Eric | EVP and Chief Medical Officer | May 05 '26 | Sale | 24.96 | 344 | 8,586 | 111,189 | May 06 |
| Horn Howard | Chief Financial Officer | May 01 '26 | Sale | 24.90 | 4,683 | 116,607 | 110,342 | May 04 |
| Horn Howard | Chief Financial Officer | Apr 01 '26 | Sale | 20.97 | 4,683 | 98,203 | 80,351 | Apr 02 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | Mar 10 '26 | Sale | 22.67 | 3,508 | 79,526 | 66,820 | Mar 10 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | Mar 06 '26 | Sale | 21.40 | 6,018 | 128,785 | 70,328 | Mar 10 |
| Horn Howard | Chief Financial Officer | Mar 03 '26 | Sale | 22.40 | 1,635 | 36,624 | 85,034 | Mar 03 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | Mar 02 '26 | Sale | 22.80 | 8,135 | 185,478 | 76,346 | Mar 03 |
| Pinion John Richard | See Remarks | Mar 02 '26 | Sale | 22.80 | 10,029 | 228,661 | 110,026 | Mar 03 |
| Harris Erik | EVP & Chief Commercial Officer | Mar 02 '26 | Sale | 22.80 | 10,539 | 240,289 | 89,515 | Mar 03 |
| KAKKIS EMIL D | President & CEO | Mar 02 '26 | Sale | 22.80 | 54,404 | 1,240,411 | 658,994 | Mar 03 |